-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220

Benzinga·11/04/2026 12:26:15
HC Wainwright & Co. analyst Matthew Caufield assumes Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $220.